MktsMarkets

Prelude Therapeutics Incorporated
NASDAQ: PRLDKey statistics
PRLD News
Stories mentioning PRLD from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 4,580 | 6,500 | 0.00 | 3,000 | ||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | ||||||
| Operating Expenses | ||||||||
| Research & Development | 13,601 | 17,992 | 21,708 | 25,784 | 28,816 | 31,620 | 29,457 | 29,509 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 18,757 | 22,988 | 26,918 | 32,194 | 34,606 | 37,831 | 37,376 | 37,164 |
| Operating Income (Loss) | (14,177) | (17,348) | (20,418) | (32,194) | (34,606) | (33,831) | (34,376) | (37,164) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 3,792 | 891.00 | 693.00 | 963.00 | 2,521 | 5,100 | 2,105 | 2,424 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (10,385) | (16,457) | (19,725) | (31,231) | (32,085) | (28,731) | (32,271) | (34,740) |
| Earnings Per Share (Basic) | (0.13) | (0.21) | (0.26) | (0.41) | (0.42) | (0.38) | (0.43) | (0.46) |
| Earnings Per Share (Diluted) | (0.13) | (0.21) | (0.26) | (0.41) | (0.42) | (0.38) | (0.43) | (0.46) |
| Weighted Average Shares Outstanding (Basic) | 82,520 | 76,956 | 76,132 | 75,994 | 75,986 | 75,806 | 75,856 | 75,762 |
| Weighted Average Shares Outstanding (Diluted) | 82,520 | 76,956 | 76,132 | 75,994 | 75,986 | 75,806 | 75,856 | 75,762 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PRLD
Prelude Therapeutics Incorporated (NASDAQ: PRLD) is a stock listed on the Nasdaq Stock Market under the ticker symbol PRLD. It last traded at $3.30 (Nov 18, 2026, 4:00 PM ET), down 0.6% on the day. That gives Prelude Therapeutics a market capitalisation of $265.3M.
Over the past 52 weeks PRLD has traded between $1.29 and $6.83.
Revenue for the quarter ended Mar 31, 2026 was $4.6M; a net loss of $10.4M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $4.6M | -$10.4M | -226.7% |
| Dec 31, 2025 | — | -$16.5M | — |
| Sep 30, 2025 | $6.5M | -$19.7M | -303.5% |
| Jun 30, 2025 | — | -$31.2M | — |
From Prelude Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…